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a  b  s  t  r  a  c  t
Carthami  ﬂos,  the dried  ﬂoret  of Carthamus  tinctorius  L.,  Asteraceae  (safﬂower),  has  been  widely  used  in
traditional  Chinese  medicine  to treat a broad  range  of  ailments,  such  as coronary  heart disease,  angina
pectoris,  gynecologic  disease,  stroke,  and  hypertension.  However,  although  several  studies  on Carthami
ﬂos have  been  done  consecutively,  the  results  are  usually  scattered  across  various  documents.  This  review
aims to  provide  up-to-date  information  on the  traditional  uses,  pharmacology,  clinical  applications,  and
toxicology  of  Carthami  ﬂos  in  China  and  thereby  to  provide  a basis  for further  investigation  of its use
to treat  dissimilar  diseases.  Various  ethnomedical  uses  of Carthami  ﬂos  have  been  documented  in  many
ancient  Chinese  books.  Crude  extracts  and  isolated  compounds  from  Carthami  ﬂos show  a  broad  range
of  pharmacological  properties,  such  as protective  effects  on  brain  tissue,  on osteoblasts,  and  in  myocar-
dial  ischemia,  as  well  as anti-inﬂammatory,  antithrombotic,  antitumor,  and  antidiabetic  activities.  To
date,  safﬂower  and  safﬂor  yellow  injections  have been  used  to treat  coronary  heart  disease,  chronic  pul-
monary  heart  disease,  cerebrovascular  diseases,  orthopedic  diseases,  and diabetes  mellitus.  Regarding
the toxicology  of Carthami  ﬂos,  among  the  side  effects  that  have  been  observed  are  allergic  reaction,
spermatogenetic  failure,  fatty  liver,  and  nephrotoxicity.
©  2015 Sociedade  Brasileira  de  Farmacognosia.  Published  by Elsevier  Editora  Ltda.  All  rights  reserved.ntroduction
Carthami ﬂos, the dried ﬂoret of Carthamus tinctorius L., Aster-
ceae (safﬂower), has been commonly used in traditional Chinese
edicine to treat a wide range of ailments, such as coronary heart
isease, angina pectoris, gynecologic disease, stroke, and hyper-
ension. In China, Carthami ﬂos has been used as medication for
ore than 2100 years, since the species was introduced by Zhang
ian in the historic “Silk Road.” Traditional Chinese medicine has
ccumulated ponderable information on the use of Carthami ﬂos,
hich has been documented in ancient manuscripts and summa-
ized in recently published books, such as Chinese Pharmacopoeias,
Newly Revised Canon of Materia Medica,” and “Medical Treasures
f the Golden Chamber.” Modern pharmacological investigations
ave substantiated that Carthami ﬂos extracts or isolated pure com-
onents have protective effects on brain tissue, myocardial tissue,
nd osteoblasts, as well as antithrombotic, anti-inﬂammatory, and
ntitumor effects, which, to some degree, are tightly linked to the
∗ Corresponding author.
E-mails: sssnmr@63.com (L. Sun), mlguo@26.com (M.  Guo).
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http://dx.doi.org/10.1016/j.bjp.2015.06.001
102-695X/© 2015 Sociedade Brasileira de Farmacognosia. Published by Elsevier Editoraaccounts of blood circulation promotion, blood stasis removal, and
pain relief recorded in ancient Chinese documents.
Thus far, many compounds have been isolated from Carthami
ﬂos, including quinochalones, ﬂavonoids, alkaloids, polyacetylene,
aromatic glucosides, organic acids, etc. (Guo and Zhang, 1998, 2000;
Zhang et al., 2004, 2005, 2006, 2009a; Asgarpanah and Kazemivash,
2013; Zhou et al., 2014). Effective compounds or active parts
of Carthami ﬂos have been screened for pharmacological activity
in vivo and in vitro, suggesting good repercussions for human health
maintenance and promotion. Some compounds have been applied
to clinical treatment of coronary heart disease, chronic pulmonary
heart disease, cerebrovascular diseases, orthopedic diseases, and
diabetes mellitus. This paper introduces the ethnopharmacological
application, pharmacological properties, modern clinical applica-
tion, and side effects of Carthami ﬂos in China and thereby provides
support and evidence for further investigation of its use.
Ethnopharmacological useIn traditional Chinese medicine, the application of Carthami ﬂos
in clinical treatment can be traced back to as early as 2000 years
ago. The book Medical Treasures of the Golden Chamber, writ-
ten by Zhang Zhongjin, documented that, when given as a cold
 Ltda. All rights reserved.
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nfusion, the decoction of Carthami ﬂos and distillate spirit (1:10)
ad therapeutic effects on gynecological diseases, including induc-
ion of abortion early in pregnancy, expulsion of a retained
fterbirth or stillbirth, and moderation of pain during menstrual
eriods. Given as a major medicament portion, Carthami ﬂos has
een used as a remedy for coronary heart disease, angina pectoris,
ypertension, and gynecological diseases (Guo and Zhang, 1996,
999). The leaves are used as a diuretic, an appetizer, and a cure for
rinary discharge. Also, powder made from leaves of safﬂower com-
ining with Cortex Lycii Radicis could be used to clavus after adding
esame oil to be pasty. Due to the impact of speciﬁc geographic
nvironments, customs, and cultures, the medicinal properties and
linical applications of Carthami ﬂos differ across various ethnic
egions of China. In Mongolian and Tibetan medicine, Carthami ﬂos
s used to treat liver metabolism disorders, such as hepatomegaly,
epatic injury, xantho eyes, and heat hepatic blood (Luo, 1988). In
ai and Yi medicine, the nature of Carthami ﬂos is similar to that
n Chinese medicine, but its clinical applications are mainly aimed
t treating infertility, galacturia, soft tissue injuries, and fractures
Lin et al., 2003; Guan, 1993). Modern medical investigations have
hown the activities of Carthami ﬂos in improving oxygen supply
o the heart and brain, mitigating ischemic injury, and hepatopro-
ection, which, to some extent, provide scientiﬁc support for the
raditional medicinal theory and application of Carthami ﬂos (Chen
t al., 2012).
harmacological reports
ffect on brain injury
Hydroxysafﬂor yellow A (HSYA) (1), a major active chemical
ngredient of Carthami ﬂos, has been widely researched in China
s a treatment for cerebrovascular diseases (Li et al., 2005, 2010;
hang et al., 2009a,b; Feng et al., 2010; Tang et al., 2010). Numer-
us studies have indicated a protective ability of HSYA (1) against
rain impairment. An in vitro study corroborated that interference
ith HSYA (1) (0.072 mg/ml) contributed to nerve regeneration of
n organotypic hippocampal slice from neonatal SD rats in nor-
al  or ischemic conditions (Qin et al., 2012a; Chart 1). HSYA (1)
lso relieved oxygen-glucose deprivation in neural stem cell injury
nd contributed to neurogenesis in vitro (Qin et al., 2012b; Chart
). Neuron damage induced by exposure to glutamate and sodium
yanide (NaCN) in cultured fetal cortical cells was  signiﬁcantly
nhibited by HSYA (1) (Zhu et al., 2003; Chart 1). In an in vivo study,
he therapeutic effect of HSYA (1) on focal cerebral ischemia was
nvestigated in a middle cerebral artery occlusion (MCAO) model.
eginning with a dose of 3 mg/kg, HSYA (1) suppressed throm-
osis formation in MCAO rats, followed by inhibition of platelet
ggregation and adjustment of PGI2/TXA2 (Zhu et al., 2003, 2005;
hart 1). Spinal cord ischemia–reperfusion injury in rabbits was
lso found to improve when treated with HSYA (10 mg/kg) (Shan
t al., 2010; Chart 1). An investigation of its effect on mitochon-
rial permeability transition pores (mtPTP) in rat brain indicated
hat HSYA (1) (10–80 mol/l) inhibited Ca2+-induced swelling of
itochondria isolated from rat brains and generation of ROS. Taken
ogether with the improved mitochondrial energy metabolism,
he enhanced ATP levels, and the respiratory control ratio, it was
xtrapolated that HSYA (1) inhibited the opening of mtPTP by a free
adical-scavenging action in the brain, which consequently may
ave resulted in the neuroprotective effect (Tian et al., 2008). In
 study by Pan et al. (2012), HSYA (1) (5 mg/kg, i.p.)  was found to
ttenuate brain injury induced by lymphostatic encephalopathy,
hich showing alleviating neurologic deﬁcits and cell apopto-
is in the rostral ventrolateral medulla (RVLM), suppressing the
mpaired regulatory roles of the autonomic nervous system inacognosia 25 (2015) 553–566
cardiovascular, and preventing the decrease of endothelial nitric
oxide synthase (eNOS) mRNA. Additionally, pretreatment with
HSYA (1) improved spatial memory deﬁcits and inhibited changes
in the blood–brain barrier, the SOD activity, and the malondialde-
hyde content in brain injury induced by 12C6+ particle therapy
(Gan et al., 2012). A recent work implied that HSYA (1) has a
protective effect against cerebral I/R injury, partly by reducing
apoptosis through the PI3K/Akt/GSK3b signaling pathway (Chen
et al., 2013a,b; Chart 1) and decreasing nitrotyrosine formation (Sun
et al., 2013). Based on these studies, it was  hypothesized that the
underlying mechanisms of the protective effects of HSYA on brain
injury involved a reduction of lipid peroxidation, the suppression of
superoxide dismutase (SOD) and glutathione peroxidase (GSH-Px)
activities, the upregulation of the expression of endothelial nitric
oxide synthase (eNOS) protein, and a decrease in cell apoptosis
and structural damage of nervous tissues. Recent reports have sug-
gested that HSYA (1) protect cortical neurons from inhibiting the
phosphorylation of PPARr and the expression of NR2B-containing
NMDA receptors and regulating the Bcl-2 family (Yang et al., 2010;
Liu et al., 2012a,b). However, whether neuronal NOS is involved
in the protective effects of HSYA (1) remains to be determined
in a future study. An in vitro investigation also conﬁrmed that
HSYA showed protective effects on neurotoxicity induced by -
amyloid in PC12 cells, as evidenced by reversed changes triggered
by -amyloid, such as a decrease in cell viability, glutathione level,
mitochondrial membrane potential, and the ratio of Bcl-2/Bax pro-
tein expression, along with an increase in lactate dehydrogenase,
DNA fragmentation, and the levels of malondialdehyde and intra-
cellular reactive oxygen species. This ﬁnding suggested that HSYA
(1) was  a promising candidate drug for prevention and treatment
of Alzheimer’s disease (Kong et al., 2013a,b).
Investigations on the protective effects of extracts or other com-
pounds from Carthami ﬂos on the nervous system have also been
done. In an in vitro study, Zhao et al. (2009a) found that all solvents
extracted from Carthami ﬂos, which contain extracts of chloro-
form, ethyl acetate, and n-butyl alcohol (1, 10, and 100 g/ml,
respectively), markedly enhanced both dopamine uptake by Chi-
nese hamster ovary (CHO) cells stably expressing the dopamine
transporter (DAT) and norepinephrine uptake by CHO cells express-
ing the norepinephrine transporter (NET), and simultaneously
depressed serotonin uptake by CHO cells expressing the sero-
tonin transporter (SERT), indicating that extracts from Carthami
ﬂos would improve neuropsychologic disorders through regulating
the monoamine-transporter activity. Further, an in vitro investi-
gation showed that N1,N5-(Z)-N10-(E)-tri-p-coumaroylspermidine
(2) potently and selectively inhibited serotonin uptake in S6 cells
or in synaptosomes with a reversible competitive property for
5HT uptake inhibition, mirroring its effect of improving neuropsy-
chologic disorders through regulating serotoninergic transmission
(Zhao et al., 2009b; Chart 1). Carthamin (10 mg/kg) (3) signif-
icantly decreased the formation of malondialdehyde in mouse
cerebrum and of thiobarbituric acid reactive substances and 8-
hydroxy-2′-deoxyguanosine (8-OHdG) in the cerebral cortex of
rats subjected to an injection of FeCl3 solution into the sensory
motor cortex inhibited glutamate-induced (Hiramatsu et al., 2009;
Chart 1). Nicotiﬂorin (kaempferol-3-O-rutinoside) (4), a natural
ﬂavonoid extracted from Carthami ﬂos, showed neuroprotection
in focal cerebral ischemia in vitro and in vivo, which might be
attributed to the upregulation of endothelial nitric oxide syn-
thase (eNOS) activity (Li et al., 2006a,b; Chart 1). A study by
Huang et al. (2007) showed that kaempferol-3-O-rutinoside (4)
(30, 60, and 120 mg/kg) signiﬁcantly attenuated the increase of
lactic acid and malondialdehyde (MDA) contents and the decrease
in LDH, Na+K+ATPase, Ca2+Mg2+ATPase, and superoxide dismutase
(SOD) activity in multi-infarct dementia model rats, indicat-
ing its protective effects on reducing the memory dysfunction,
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Chart 1
Pharmacological activities of compounds/extract from Carthami ﬂos.
Biological activities Extract/compound (effective
dose)
Test model Remarks Reference
Protection on brain
injury
HSYA (1) (0.036 and
0.072 mg/ml)
Organotypic hippocampal slices from neonatal SD
rats (in vitro)
Increase organotypic hippocampal cells from neonatal SD rats
(DAPI+, BrdU+ and Nestin+) with arranged in cords and migrated
to the codex as compared to control (normal saline)
Qin et al. (2012a)
HSYA (1) (0.036 and
0.072 mg/ml)
Oxygen-glucose deprivation in hippocampal slice
cultures from rats (in vitro)
Reduce the proliferation of neural stem cell compared to normal
saline
Qin et al. (2012b)
HSYA (1) (10–80 mol/l) Ca2+-induced and H2O2-induced swelling of
mitochondria isolated from rat brains (in vitro)
Inhibited swelling and reactive oxygen species of mitochondria,
improve mitochondrial energy metabolism and enhanced ATP
levels and the respiratory control ratio compared to 50 mol/l
Ca2+-treated group
Tian et al. (2008)
HSYA (1) (3.0 and 6.0 mg/kg,
sublingular vein injection)
Male Wistar–Kyoto rats with middle cerebral
artery occlusion (MCAO) (in vivo)
Decrease neurological deﬁcit scores and reducing infarct area
compared to the saline group and dosage of 6.0 mg/kg show a
similar potency as nimodipine (0.2 mg/kg)
Zhu et al. (2003)
HSYA (1) (3.0 and 6.0 mg/kg,
sublingular vein injection)
MCAO rats (in vivo) Produce a dose-dependent reduction in infarct area (60% and 85%
respectively), increase the ratio of 6-Keto-PGF1a and TXB2, reduce
thrombotic weight
Zhu et al. (2005)
HSYA (1) (10.0 mg/kg, ear
intravenous injection)
Rabbits with ischemia/reperfusion (I/R) injury
(in vivo)
Attenuate I/R induced necrosis in spinal cords, alleviate oxidative
stress as indicated by decreased malondialdehyde (MDA) level and
increased superoxide dismutase (SOD) activity and protected
neurons from I/R-induced apoptosis in rabbits
Shan et al. (2010)
HSYA (1) (5 mg/kg, i.p.) Rats with lymphostatic encephalopathy-induced
brain injury (in vivo)
Alleviate the neurological deﬁcits, attenuate cell apoptosis in the
rostral ventrolateral medullus compared to saline group
Pan et al. (2012)
HSYA (1) (5,10 and 20 mg/kg,
intraperitoneal injection)
Mouse with brain injury induced by 12C6+ particle
therapy (in vivo)
Dose-dependently improve the spatiomemory deﬁcits and
increase SOD activity and reduce malondialdehyde content in
brain tissue
Gan et al. (2012)
HSYA (1) (4 and 8 mg/kg,
tail-vein injection)
MCAO rats (in vivo) Diminish the number of apoptotic cells and increase the Bcl-2/Bax
ratio as well as the phosphorylations of Akt and GSK3b
Chen et al. (2013a,b)
N1,N5-(Z)-N10-(E)-tri-p-
coumaroylspermidine (2)
(0.04–100 M)
Chinese hamster ovary cells (in vitro) Inhibit serotonin uptake in S6 cells (IC50 = 0.74 ± 0.15 M)  and in
synaptosomes (IC50 = 1.07 ± 0.23 M)
Zhao et al. (2009b)
Carthamin (3) (10 mg/kg) Rats with epileptic foci induced by iron (in vivo) Inhibit 8-hydroxy-2′-deoxyguanosine in the cerebral cortex of rats Hiramatsu et al. (2009)
Kempferol-3-O-rutinoside (4)
(2.5, 5 and 10 mg/kg, tail vein)
Rats with permanent focal cerebral ischemia
(in vivo)
Dose-dependently reduce brain infarct volume and neurological
deﬁcits compared with nimodipin (positive control)
Li et al. (2006a)
Kempferol-3-O-rutinoside (4)
(25–100 g/ml)
Cultured neurons suffered hypoxia (in vitro) Attenuate cell death and reduce lactate dehydrogenase release Li et al. (2006a)
Anti-myocardial
ischemia effect
Ethanolic extract (62.5 and
125 g/ml)
H9c2 cardiomyoblast cells (in vitro) Reduce IkB degradation and NFkB activation, activate of
anti-apoptotic proteins, Bcl-2 and Bcl-xL, stabilization the
mitochondria membrane and the down-regulation of extrinsic and
intrinsic pro-apoptotic proteins, such as TNF, active caspases-8,9
and 3 t-Bid, Bax, compared to LPS
Tien et al. (2010)
HSYA (1) (4 and 8 mg/kg, tail
vein)
Rats with coronary artery ligation (in vivo) Reduction of myocardial infarction size, superoxide dismutase
activity, endothelial nitric oxide synthase activity and nitric oxide
content, and inhibit elevation of creatine kinase activity and
malondialdehyde content
Wang et al. (2009a,b)
HSYA (1) (0.1–3 mg/kg,
intravenous injection)
Rats with pentobarbitone-anesthetized
normotensive and spontaneously hypertensive
(in vivo)
Dose-dependently reduce heart rate, mean arterial pressure, left
ventricular systolic pressure, left ventricular end-diastolic pressure
Nie et al. (2012)
N-(p-coumaroyl) serotonin (6)
(5 × 10−7 M)
Model of perfused guinea-pig Langendorff hearts
subjected to ischemia and reperfusion (in vitro)
Increase the NO level at the end of ischemia and show 63.2%
recovery rate of left ventricular developed pressure compared to
drug-free control (30.8%)
Hotta et al. (2002)
N-feruroylserotonin
(5 × 10−7 M) (7)
Similar to N-(p-coumaroyl) serotonin Show 61.0% recovery rate of left ventricular developed pressure
and quench the activity of active radicals
Hotta et al. (2002)
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Chart 1 (Continued )
Biological activities Extract/compound (effective
dose)
Test model Remarks Reference
Antithrombotic
effect
Aqueous extract (1 and
0.7 g/kg, oral)
(a) Rats arterial thrombosis model (in vivo)
(b) Rats venous (Wessler) thrombosis model
(in  vivo)
(c) Mouses with collagen/epinephrine-induced
pulmonary embolism (in vivo)
(d) Mouses tail bleeding (in vivo)
(a) Show a mild thrombosis inhibition but without difference with
control when plus clopidogrel or not
(b) Inhibit thrombus formation from 16.1 to 7.9 mg and led to a
signiﬁcant decrease in venous thrombus weight when added
clopidogrel and also augment thrombin time and prothrombin time
(c)  Increase the number of non-paralyzed animals to 33.3% and
surviving rates to 53.3%
(d) Prolonged the bleeding time when added clopidogrel
Li and Wang (2010)
Carthamins yellow (100 and
200 mg/kg, oral)
Rats with blood stasis (in vivo) Decrease the whole blood viscosity, plasma viscosity, erythrocyte
aggregation index, hematocrit and platelet aggregation when
compared with aspirin
Li et al. (2009)
HSYA (1) (1 × 10−4 M) Human EC line (EAhy926) (in vitro) Attenuate cell cycle arrest and inhibit cell apoptosis in a
concentration-dependent manner and increase the bcl-2/bax ratio,
VEGF protein concentration, VEGF mRNA expression, HIF-1a protein
accumulation and its transcriptional activity
Ji et al. (2008)
HSYA (1) (1 × 10−6, 1 × 10−5
and 1 × 10−4 M)
Human umbilical vein endothelial cells (HUVEC)
(in vitro)
Inhibit cell apoptosis and cell cycle G1 arrest induced by hypoxia
Increase the Bcl-2/Bax ratio of protein and NO content of cell
supernatant
Reduce p53 protein expression in cell nucleus
Ji et al. (2009)
Anti-inﬂammatory Safﬂor yellow (25 and
50 mg/kg, intraperitoneal)
Rats of pulmonary ﬁbrosis induced by bleomycin
(in vivo)
(a) Alleviate the loss in bodyweight, the increase of hydroxyproline
content in the lung tissues and pathologic changes of pulmonary
ﬁbrosis
(b)  Prevent the increase of a -SMA positive cells and TGF-b b1
expression
Wang et al. (2011a,b)
Safﬂor yellow (0.05, 0.25 and
1.25 mg/ml)
Human embryo lung ﬁbroblast (in vitro) Dose-dependently inhibit the elevation of -SMA expression and the
morphological change
Wang et al. (2011a,b)
Methanol extract (10, 50 and
100 g/ml)
RAW 264.7 macrophages (in vitro) The increase HO-1 protein expression, the reduced production of
NO,  PGE2, iNOS and COX-2, and the inhibition of (TNF)--mediated
VCAM-1 expression and NF-B luciferase activity
Jun et al. (2011)
HSYA (1) (1, 4 and 16 mol/l) Human alveolar epithelial A549 cells (in vitro) (a) Inhibit the expression of TLR-4, Myd88 ICAM-1, TNF, IL-1 and
IL-6
(b)  Inhibit the phosphorylation of p38 MAPK, the adhesion of
leukocytes to A549 cells and decrease NF-B p65 nuclear
translocation
Song et al. (2013)
HSYA (1) (5 × 10−6, 10 × 10−6
and 20 × 10−6 mol/l)
Umbilical vein endothelial Eahy 926 cells (in vitro) Inhibit the increased expression of TLR-4, IL-6, IL-1 and TNF Zhu et al. (2012)
HSYA (6, 15 and 37.5 mg/kg,
i.v.)
Mice with LPS-induced pulmonary inﬂammatory
injury (in vivo)
(a) Ameliorate pulmonary edema and inﬂammatory cell inﬁltration
(b) Suppress p38 MAPK, NF-B p65 activation and alter
inﬂammatory cytokine expression (TNF-, IL-1, IL-6 and IL-10)
Sun et al. (2010)
HSYA (1) (26.7, 40 and
60 mg/kg/day, intraperitoneal
injection)
Mice with bleomycin-induced pulmonary injury
(in vivo)
Attenuate the loss in body weight, the increase of myeloperoxidase
activity and pathologic changes of pulmonary inﬂammation
(c) Attenuate the increased expression of TNF-, IL-1 and TGF-1,
the  increased activation of NF-B and phosphorylation of p38 MAPK
Wu et al. (2012a,b)
Hepatoprotective
effect
HSYA (1) (5 mg/kg/day for 12
weeks, oral)
Rats with CCl4-induced hepatic ﬁbrosis (in vivo) The decrease in ﬁbrosis and expression of -SMA protein, MEF-2C
gene, T-RI, T-RII, MEKK3, MEK5, and phosphorylation of ERk5
Zhang et al. (2011, 2012a,b,c)
HSYA (1) (10 mg/kg,
intraperitoneal injection)
Rats with hepatic ﬁbrosis induced by oxidative
stress (in vivo)
(a) Increase the activities of antioxidant enzymes and reduce -SMA
level.
(b)  Up-regulating the expression of PPARr and MMP-2, and down
regulating the expression of TGF-1 and TIMP-1
Wan  et al. (2013)
Carthamus red (5, 10 and
20 mg/kg, oral)
Rats with CCl4-induced hepatic ﬁbrosis (in vivo) (a) Lower the serum levels of ALT, AST, ALP and total protein in liver
damage rat models
(b) Up-regulate Nrf2, GST and NQO1 expressions were at the
protein level
(c) Elevate the activities of antioxidant enzymes and level of GSH
and  lessen the content of TBARS compared to silymarin
Wu et al. (2013)
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nergy metabolism failure, and oxidative stress that are involved
n multi-infarct dementia. Additionally, postischemic treatment
ith kaempferol-3-O-glucoside (7.5 mg/kg) (5) showed a neuro-
rotective effect in focal cerebral ischemia–reperfusion rats. The
echanism of these kaempferol ﬂavonoid effects was attributed
o anti-neuroinﬂammatory activity by inhibiting the activation
f STAT3 and NF-kB p65, including independent and dependent
athways of IkB degradation and the subsequent expression of
ro-inﬂammatory mediators (Yu et al., 2013). Nevertheless, more
harmacological evaluations in animal models relating to neuro-
ogical disorders need to be considered in future studies to explain
he underlying mechanisms of these compounds.
ffects on myocardial ischemia
Ethanolic extract of Carthami ﬂos (62.5 g/ml) has the ability to
uppress JNK activity and inhibit LPS-induced TNF activation and
poptosis in H9c2 cardiomyoblast cells (Tien et al., 2010; Chart 1).
n an in vivo study, the protective effects of a puriﬁed extract from
arthami ﬂos (100, 200, 400, and 600 mg/kg body wt.) on myocar-
ial ischemia was assessed in a model of myocardial ischemia
njury induced by left anterior descending coronary artery (LAD)
cclusion, which resulted in reduced infarct size and improved
ardiac function (Han et al., 2009). Further investigations have
eported that this cardioprotective effect of Carthami ﬂos extract
200 mg/kg) was not only supported by decreased levels of cre-
tine kinase (CK) and LDH but, further, could be strengthened by
dding Panax notoginseng (Burk) F.H. Chen (EPN) extract (50 mg/kg)
Han et al., 2013a,b). HSYA (1) (4 or 8 mg/kg) also showed a
ardioprotective effect, as evidenced by the reduced myocardial
nfarction size in rats with acute myocardial ischemia induced by
AD ligation (Wang et al., 2009a,b). Whether the protective effect
f HSYA (1) on myocardial ischemia injury could be enhanced byacognosia 25 (2015) 553–566 557
combination with EPN remains inconclusive (Fu et al., 2011).
Contrarily, extracellular Ca2+ inﬂux through receptor-operated
Ca2+channels and potential-dependent Ca2+channels could be
blocked by crude drug of Carthami ﬂos (Liu et al., 2005). A further
ﬁnding showed that HSYA (1) markedly reduced Ca2+ inﬂux on car-
diac cells, as well as decreased the contractile force and heart rate
in rats. Such an effect may  implicate the activation of BKCa and KATP
channels (Nie et al., 2012; Chart 1). Whether HSYA (1) could lower
the peripheral resistance remains under study. Other compounds,
such as N-(p-coumaroyl) serotonin (6) and N-feruroylserotonin
(7), showed cardioprotective effects on isolated guinea pig
Langendorff hearts subjected to normothermic global ischemia and
subsequent reperfusion, speculated that this was in close associa-
tion with the synthesis of high phosphorous energy, ATP, which
was constituted an important part of the regulatory mechanisms
involved in myocardial ischemic injury (Hotta et al., 2002). As
evidenced by these ﬁndings, the mechanisms responsible for the
cardioprotective effects may  be partially achieved by scaveng-
ing of ROS, mediating the PI3K signaling pathway, and regulating
superoxide dismutase activity and endothelial nitric oxide synthase
activity.
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ntithrombotic effect
The aqueous extracts of Carthami ﬂos have been shown to be
ore efﬁcient than clopidogrel against venous thrombosis and pul-
onary embolism, with similar functions to carthamus yellow (Li
nd Wang, 2010; Li et al., 2009; Chart 1). An HSYA (1) activity of
nhancing the survival of vascular endothelial cells under hypoxia
as also been found, which may  be correlated with its effect on
pregulation of the HIF-1a-VEGF pathway and regulation of Bcl-
/Bax (Ji et al., 2008; Chart 1). A further investigation showed
hat HSYA (1) could protect human umbilical vein endothelial cells
HUVECs) from hypoxia-induced injury by inhibiting cell apoptosis
nd cell cycle arrest, partly indicating the molecular mechanism
f HSYA (1) in the treatment of ischemic heart disease (Ji et al.,
009; Chart 1). Contrarily, carthamin (3) (10 mg/l) could repair
he blocked HUVEC migration and reﬁnement of the f-actin struc-
ure caused by modeled microgravity (MMG), which would provide
 new alternative for intervention in cardiovascular dysfunction
part from HSYA (1).
nti-inﬂammatory effect
In a study by Wang et al. (2010), Carthami ﬂos aqueous extract
nd carthamus yellow (CY) were examined regarding their effects
n LPS-induced inﬂammatory response in a murine macrophage
ell line RAW264.7 model. According to the results, aqueous extract
rom Carthami ﬂos (1–1000 g/ml) and CY (1–2000 g/ml) sup-
ressed the production of NO, PGE2, and IL-1 and decreased
he iNOS and cyclooxygenase-2 (COX-2) protein expression levels
n LPS-induced RAW264.7 macrophages. Based on the inhibition
f cytosol IB- protein degradation and phospho-NF-B  protein
xpression, it was theorized that aqueous extract from Carthami
os and CY may  inhibit LPS-stimulated expressions of the iNOS
nd COX-2 genes through the inactivation of NF-B. As an effec-
ive part of the aqueous extract of Carthami ﬂos,  safﬂor yellow (SY)
as shown an inhibitory effect on pulmonary ﬁbrosis in vivo and
n vitro, supported by suppressing the expression of a-smooth mus-
le actin (a-SMA) (Wang et al., 2011a,b; Chart 1). Regarding the
nti-inﬂammatory action of methanol extracts of safﬂower (MEC),
t has been reported that MEC  triggered heme oxygenase-1 expres-
ion through Nrf2 (NF-E2-related factor) translocation and NF-kB
ctivity inhibition. This potential molecular mechanism has pro-
ided other clues on the molecular mechanism underlying the
nti-inﬂammatory action of aqueous extract from Carthami ﬂos
nd CY (Jun et al., 2011; Chart 1). Contrarily, polysaccharides from
arthami ﬂos were found to have immunomodulating activities that
ffectively activated the NF-kB signaling pathway through TLR4 and
nduced the production of various cytokines (IL-1, IL-6, IL-12, and
FN-) by peritoneal macrophages (Ando et al., 2002).
Recent investigations on HSYA (1) have focused on the treat-
ent of acute lung injury (ALI). The effects of HSYA (1) on ALI
ave been evaluated in vitro (human alveolar epithelial A549 cells
nd umbilical vein endothelial cells (Eahy 926 cells)) and in vivo
LPS-induced and BLM-induced ALI mice), which all manifested
hat HSYA (1) ameliorated acute lung injury by suppressing both
38 MAPK (mitogen-activated protein kinase) phosphorylation and
F-B activation, subsequently leading to a dramatic reduction
n inﬂammatory cell inﬁltration and pro-inﬂammatory cytokine
xpression in lung tissue, as well as pulmonary edema and respi-
atory dysfunction (Sun et al., 2010; Song et al., 2013; Zhu et al.,
012; Wu  et al., 2012a,b; Chart 1). Due to the high water solubility
f HSYA (1), these ﬁndings imply that HSYA (1) may  target the cell
embrane and then interfere with the interplay of receptors and
heir speciﬁc ligands (such as microbial ligands, pro-inﬂammatory
ytokines, growth factors, etc.) to regulate downstream signal
ransduction pathways so as to exert its effects. However, theacognosia 25 (2015) 553–566
concrete mechanism by which HSYA alters intracellular signaling
still warrants further studies.
Other compounds have anti-inﬂammatory effects as well. Com-
pared with ginkgolide B (IC50 5.45 × 10−6 mol/l), safﬂoquinoside A
(8) (10−5 mol/l) exhibited 54.3% inhibitory rate on the release of
-glucuronidase from rat polymorphonuclear neutrophils (PMN),
which was  induced by the platelet-activating factor (PAF), suggest-
ing its anti-inﬂammatory activity (Jiang et al., 2010).
Antitumor effect
Carthami ﬂos has been applied in cancer adjuvant therapy in
traditional medicine. Modern pharmacological experiments have
conﬁrmed the antitumor activity of Carthami ﬂos in vitro and in
vivo. Herbal extract of Carthami ﬂos (40 mg/ml) has antiprolifera-
tive and proapoptotic effects on hepatic stellate cells, which may
act by regulating the gene expression of Fas and Bcl2 pathways
(Chor et al., 2005). Further in vitro experiments have shown that
safﬂor yellow B (9) (1, 10, and 100 nmol/l) protected pheochro-
mocytoma (PC12) cells from H2O2-induced injury and apoptosis
through antioxidant and antiapoptotic mechanisms that are linked
to suppressing caspase-3 activity and Bax expression and increas-
ing Bcl-2 synthesis (Wang et al., 2009a,b). Another in vitro study
by Zhang et al. (2012a,b,c) reported that polysaccharide S of
Carthami ﬂos (0, 0.02, 0.04, 0.08, 0.16, 0.32, 0.64, and 1.28 g/l)
could restrain the proliferation of SMMC-7721 and enhance the
apoptosis of SMMC-7721 in a dose- and time-dependent man-
ner, as shown by the increased Bax expression and the decreased
Bcl-2 expression and mitochondrial membrane potential. How-
ever, HSYA (1) (0.028 g/l) inhibited the growth of a transplanted
BGC-823 tumor through inhibition of tumor vascularization (Xi
et al., 2012). Carthamin (3) dose-dependently (10−5, 10−4, and
10−3 mol/l) induced the K562 leukemic cells to the haemoglobin
end cells, the mechanism behind which remains unknown (Wu
et al., 2012a,b). In vivo, Chang et al. (2011) showed in vivo the anti-
tumor activities of Carthami ﬂos-treated dendritic cell vaccine in
JC (mouse mammary adenocarcinoma) tumor-bearing mice, rele-
vant to the polarization toward Th1 cytokines and the increase in
cytotoxic T lymphocytes. This ﬁnding further supports the report
regarding the effectiveness of Carthami ﬂos in breast cancer (Loo
et al., 2004). As determined from these studies, the mechanism
responsible for the antitumor activity of Carthami ﬂos may  occur
partly by suppressing caspase-3 activity and Bax expression and
by increasing Bcl-2 synthesis, as well as by inhibiting tumor vas-
cularization. Inhibition of human tyrosinase activity increased
with increasing concentrations of kinobeon A (10) with the use
of l-tyrosine or l-3,4-dihydroxyphenylalanine (l-DOPA) as the
substrate (Kanehira et al., 2003a,b). Recent work has uncovered
that carthamus yellow reduced the activity of mushroom tyrosi-
nase in a dose-dependent manner (IC50 1.01 ± 0.03 mg/ml) and
showed a mode of competitive inhibition with a Ki of 0.607 mg/ml.
Moreover, carthamus yellow clearly decreased the melanin
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roduction of B16F10 melanoma cells at concentrations of
.0 mg/ml, indicating no cytotoxicity (Chen et al., 2013a,b). As
erived from these studies, Carthami ﬂos has the potential to
ecome a useful skin-whitening agent or a potent natural tyrosi-
ase inhibitor in the future.
ffect on osteoblasts
In a study by Choi et al. (2010), extract of Carthami ﬂos
2–10 g/ml) was shown to inhibit osteoclastogenesis by modu-
ating the receptor activator of nuclear factor-kB ligand (RANKL)
ignaling in MC3T3-E1 cells. Recently, evaluations of the effects of
ther compounds on bone have been carried out. Liu et al. (2011a,b)
ound that SY (1.6 mg/ml) promoted the repair of injured ten-
on in Leghorn chicken, manifested by the enhanced expression
f bFGF and collagen type I protein. Also, HSYA (1) downregu-
ated the expression of TLR4 mRNA callus osteoblasts (Lu and Tu,
012). These results may  have therapeutic implications in treating
steoporosis and other bone erosive diseases, such as rheumatoid
rthritis or metastasis associated with bone loss.
ther effects
HSYA (1) has been found to alleviate carbon tetrachloride (CCl4)-
nduced liver ﬁbrosis in rats, in part through inhibition of hepatic
tellate cell (HSC) activation and MAP  kinase extracellular regu-
ated kinase 5 (Erk5) signaling (Zhang et al., 2011, 2012a,b,c; Chart
), suggesting that HSYA (1) can target ﬁbrogenic pathways and
herefore may  be a potential therapy for hepatic ﬁbrosis. A fur-
her work has reﬂected that the protective effect of HSYA (1) on
epatic ﬁbrosis induced by oxidative stress requires the activation
f PPARr (Wan  et al., 2013; Chart 1). Regarding other compounds,
arthamus red has been reported to have a hepatoprotective effect
n rats with CCl4-induced liver damage, which might be mediated
y induction of antioxidant defense through increased activation
f the Nrf2 pathway (Wu  et al., 2013; Chart 1).
Compared with glibenclamide, hydroalcoholic extract
f Carthami ﬂos (200 mg/kg) has an antidiabetic activity inacognosia 25 (2015) 553–566 559
alloxan-induced diabetic rats, as shown by their decreased fasting
blood sugar, triacylglyceride, cholesterol, LDL-C, and VLDL-C levels,
as well increased insulin levels (Asgary et al., 2012). Diabetes is
usually accompanied by increased production of free radicals
or impaired antioxidant defenses (Cuerda et al., 2011; Kuroki
et al., 2003; Maritim et al., 2003). Previous studies have disclosed
Carthami ﬂos constituted a good source of antioxidant compounds
with free radical-scavenging potential (Choi et al., 2010; Zhao
et al., 2012; Hiramatsu et al., 2009; Kanehira et al., 2003a,b;
Kambayashi et al., 2005), suggesting that it could be useful in
the prevention of diseases in which free radicals are implicated.
Considering their effects on these lipid components and their
antioxidant activity, Carthami ﬂos and its active compounds can
be assumed to be potential hypolipidemic agents that could
yield considerable advantages for both the diabetic condition
and the associated atherosclerosis or hyperlipidemic conditions.
Recently, an in vitro study further corroborated that HSYA (1)
(10–100 mol/l) ameliorated methylglyoxal-induced injury in
cultured human brain microvascular endothelial cells, as shown
by the decreased expression of caspase-3 and the accumulation
of advanced glycation end products. These results are reminiscent
of the potential of HSYA as a novel strategy for protecting against
vascular complications associated with diabetes (Li et al., 2013).
Liu et al. (2012a,b) reported that administration of Carthami ﬂos
to ethylene glycol (EG)-fed rats led to a signiﬁcant reduction in
CaOx crystal formation, indicating its antilithic effect. Meanwhile,
safﬂower yellow (50 mg/l) can protect human renal tubular epithe-
lial cell lines (HK-2 cells) from damage by inhibiting apoptosis
induced by aristolochic acid, which may be affected by suppressing
the activation of caspase-3. These ﬁndings suggest that safﬂower
yellow may  be beneﬁcial to the treatment of aristolochic acid
nephropathy.
An in vivo study by Lu et al. (2008) showed that menopro-
gen, a herbal formula consisting of Lycii fructus,  Rehmanniae radix,
Mori fructus,  and Carthami ﬂos, signiﬁcantly increased the levels of
serum estradiol and progesterone but reduced the levels of follicle-
stimulating and luteinizing hormones in rats.
The 5a-reductase inhibitory and hair growth-promoting activ-
ities of Carthami ﬂos ethanolic extract were tested in C57BL/6
mice, which resulted in a ﬁnasteride equivalent 5a-reductase
inhibitory activity (FEA) value of 24.30 ± 1.64 mg per 1 g crude
extract (Kumara et al., 2012). This ﬁnding may  lead to new alterna-
tive medicines for hair loss prevention and treatment.
An in vitro study of the anti-gammaherpesvirus activity of n-
hexane and EtOH fractions of Carthami ﬂos extracts (iSLK-BAC16
and iSLK-puro cells) by Lee et al. (2013) indicated that n-hexane
and EtOH fractions of Carthami ﬂos extracts critically inﬂuenced
two stages of the Kaposi’s sarcoma herpesvirus (KHSV) life cycle by
abnormally inducing KSHV lytic reactivation and severely preven-
ting KSHV virion release from the viral host cells. Simultaneously,
the mechanism of dysregulation of KSHV replication by Carthami
ﬂos extracts may  be mediated by dysregulating the cell cycle and
producing strong cytotoxicity. Based on this ﬁnding, studies to
gather more in vitro and in vivo evidence on the anti-gamma her-
pesvirus activities of Carthami ﬂos extracts and the causes of cellular
cytotoxicity are needed. In vivo, Carthami ﬂos extract (200 and
400 mg/kg) showed similar reductions in the volume, free acidity,
and total acidity of gastric secretion induced by carbachol, such
as cimetidine and verapamil, indicating its antiulcerogenic effect
(Mandade et al., 2012). As reported by Liu et al. (2005), Carthami
ﬂos has a natural calcium channel blocking activity, which may  have
contributed to its antiulcerogenic effect. Further studies to evalu-
ate the exact mechanism of this effect are suggested. Recently, the
photoprotective activity of topical HSYA (1) (100 and 200 g per
mouse) was investigated in a UV-induced photoaging mice model.
The results showed clear recovery of UV-induced skin damage,
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hich could possibly be attributed to the antioxidative property
f HSYA (1) and activated by promoting endogenous collagen syn-
hesis (Kong et al., 2013a,b).
linical applications
reatment of coronary heart disease
In a study by Huang (2013; Chart 2), patients with coronary heart
isease (CHD) treated with safﬂower injection showed a decrease in
emodynamic parameters, containing the whole blood, high shear
iscosity, shear whole blood viscosity, whole blood viscosity and
lasma viscosity, which were lower than those of the control group
reated with Salvia miltiorrhiza injection, suggesting the clinical
fﬁcacy of safﬂower injection in coronary heart disease. In another
tudy, safﬂower injection was found to improve the clinical symp-
oms of angina pectoris and the electrocardiogram of CHD patients
ompared with groups treated only with conventional western
edicine (Su and Chai, 2011; Chart 2). The major active ingredient
f Carthami ﬂos, safﬂor yellow, has also been used to treat coro-
ary heart disease. A study by Liu et al. (2011a,b) found that safﬂor
ellow could reduce the endothelin, matrix metalloproteinase-9,
nd high-sensitivity C-reactive protein of different patients with
oronary artery disease (Chart 2). Other studies have shown that
afﬂor yellow could decrease neuropeptide Y, which was impor-
ant to improve the pathogenetic condition of patients (Liu et al.,
008; Chart 2).
reatment of chronic pulmonary heart disease
The use of safﬂower injection to treat heart failure in patients
ith chronic pulmonary heart disease (CPHD) resulted in improved
eart function, as proved by the ameliorative blood gas parame-
ers compared with the control group (p < 0.05) (Liao, 2012; Chart
). contrarily, recent studies on SY and SY injection have indicated
heir curative function in pulmonary heart disease. An investiga-
ion by Chen et al. (2014) showed the efﬁcacy of SY in improving
T segment depression (p < 0.01) and decreasing the levels of TnI,
K-MB, and CRP (p < 0.05), thereby protecting myocardial injury
rom CPHD (Chart 2). Meanwhile, the pulmonary function, as well
s blood viscosity and rheology, of patients with CPHD was  found
o be ameliorated after treatment with SY injection (Ren and Mei,
014; Chart 2).
reatment of cerebrovascular diseases
Extracts and compounds from safﬂower have been applied with
eneﬁcial effects in the clinical treatment of cerebrovascular dis-
ases. Systemic evaluations of the clinical effect and safety of
afﬂower injection in the treatment of acute ischemic stroke have
ndicated that such injection is helpful in improving neurologic
unctional deﬁcits and has a good safety proﬁle, as shown by the
eta-analysis results on total effective rates, the relative risk 99%
redible region (99% CI), the number of treatments needed (99% CI),
nd the weight mean deviation (99% CI), which are 1.19 (1.10, 1.28),
.14 (5.00, 12.5), and −0.62 (−1.10, −0.15), respectively (Ma  et al.,
012). The latent mechanism was partially involved in decreasing
he serum ratio of IL-6/IL-10 and suppressing the lipid peroxidation
y increasing the level of superoxide dismutase, choramphenicol
cetyltransferase, and malondialdehyde, which were supported by
linical evidence from Luo et al. (2014; Chart 2). Also, injections of
afﬂower yellow and HSYA have been reported to be more effec-
ive in clinical treatment of acute ischemic stroke compared with
inkgo leaf extract and dipyridamole injection (Xiao and Hu, 2011;
ing et al., 2008; Chart 2).acognosia 25 (2015) 553–566
Treatment of orthopedic diseases
Recently, clinical observations of safﬂower injection in ortho-
pedic diseases have been gradually carried out, with good echo.
Safﬂower injection for patients with acute gouty arthritis showed
equal efﬁcacy to treatment with colchicine, suggesting that saf-
ﬂower injection may  be a new alternative treatment for acute gouty
arthritis patients due to its low toxicity (Li et al., 2011; Chart 2). A
clinical report by Sui et al. (2011) pointed to the application of saf-
ﬂower injection in isolated limb replantation, which resulted in 95%
survival of replanted ﬁngers with no adverse effect, exceeding the
86% survival rate in the control group. An observation of its preven-
tion of postoperative tendon adhesion in ﬂexor tendon injury has
also been conducted, which resulted in 60 patients being healed in
stage I and showing an advantage over the dickon biological ﬁlm
group in terms of total active motion of the tendon after four weeks.
No obvious discrepancy in power to grasp was  observed, which
was reminiscent of the apotropaic effect of safﬂower injection on
postoperative tendon adhesion in ﬂexor tendon injury (Choi et al.,
2013).
Treatment of diabetes mellitus and its complications
In a clinical report by Wei  (2011; Chart 2), safﬂower injection
was extrapolated to effectively postpone the development of renal
failure caused by diabetic nephropathy on the basis of routine treat-
ment. Similarly, the application of safﬂower yellow injection in
diabetic nephropathy obtained beneﬁcial results in palliating urine
protein and lowering the serum creatinine level of patients (Yang
et al., 2011; Chart 2; Qiu et al., 2013). Other complications of dia-
betes mellitus that could be treated with safﬂower yellow injection
have been reported. Diabetic peripheral neuropathy, a frequent
chronic complication of diabetes mellitus, could be ameliorated by
safﬂower yellow injection, which may  be implicated in ameliora-
tion of microcirculation in patients (Yang and Dai, 2010; Chart 2). In
a recent clinical observation, safﬂower yellow injection was found
to decrease the incidence of delayed graft function and thereby
improve recovery of graft function after renal transplantation (Pang
et al., 2014; Chart 2).
Side effects
An in vivo study of the acute toxicity of carthamus red showed
no toxicity and mortality for doses of up to 2000 mg/kg (Wu et al.,
2013). However, some side effects have been reported in animal
and human models. After being given orally (by gavage method)
to mice at a dose of 200 mg/kg for 35 consecutive days, Carthami
ﬂos extract engendered the formation of multinucleated giant cells
in the germinal epithelium and resulted in a marked decrease in
epithelial vacuolization, germ sloughing and detachment, sem-
iniferous tubule diameter, seminiferous epithelium height, and
maturation arrest, suggesting its ability to change the testis histo-
logic structure and cause spermatogenetic failure (Mirhoseini et al.,
2012; Bahmanpour et al., 2012). Therefore, precautions should be
taken when using Carthami ﬂos extract on men  who  are infertile
or have reproductive disorders. Tests of active systemic anaphy-
laxis and passive cutaneous anaphylaxis by Carthami ﬂos injection
have shown positive reactions in guinea pigs and SD rats, respec-
tively, indicating its sensitization to allergic reaction (Zhang et al.,
2012a,b,c). An essential requirement for future studies is the explo-
ration of the recessive sensibilizing substance in Carthami ﬂos
injection. With the increasing clinical application of Carthami ﬂos,
side effects have been gradually reported, such as inducing angle-
closure glaucoma, throat inﬂammation and rhinorrhagia (Deng,
2012). Additionally, daily intraperitoneal injection of HSYA at a
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Chart 2
Summary of clinical trials.
Author (Date) Design duration Condition No. of participants
randomized (age)
Intervention Comparison Main results between
groups
Adverse events Authors conclusion
Huang (2013) 40 days Coronary heart
disease (CHD)
122 (57.33 ± 15.02) Injected with 20 ml
safﬂower injection
with 0.5% 250 ml
glucose injection once
a  day
Salvia injection The hemodynamic
parameters, were lower
than Salvia injection
(p < 0.05)
None reported Safﬂower injection
has efﬁcacy in CHD
and could improve
heart function
Su and Chai
(2011)
2 weeks CHD 100; 50 per group
(42–75 years)
Usual western
medicine treatment
and Intravenous with
40 ml  safﬂower
injection with 0.5%
250 ml glucose
injection
Usual western
medicine treatment
The clinical symptoms and
electrocardiogram results
in treated group were
better than the group only
treated with western
medicine (p < 0.05)
None reported Safﬂower injection
could make usual
western medicine
treatment better in
aspect of
controlling angina
pectoris of CHD
Liu et al. (2008) 9 days Unstable angina
pectoris
72; 36 treated with
safﬂor yellow; 36
treated with
nitroglycerin
(61.7 ± 12.2)
Intravenous with
80 mg safﬂor yellow
once a day
Intravenous with
10 mg nitroglycerin
Pretherapy neuropepite Y
level was
(228.5 ± 29.8)pg/ml in
safﬂor yellow group,
(237.6 ± 27.9) pg/ml in
nitroglycerin group.
Neuropepite Y level of
post-treatment was
(149.5 ± 24.3) pg/ml in
safﬂor yellow group,
(181.8 ± 23.7) pg/ml in
nitroglycerin group
None reported Neuropepite Y
could be a index in
observing change
of unstable angina
pectoris. Safﬂor
yellow could
improve oxygen
supply in
myocardium
Miao et al.
(2010)
14 days CHD with
heart-blood
stagnation
syndrome
439; 330 in test group;
109 in control group
(18–65)
Test group received
safﬂor yellow injection
5  ml  (250 mg)  in 0.9%
NaCl 250 ml
Given safﬂower
injection 20 ml in 0.9%
NaCl 250 ml
The total effective rate on
angina pectoris and
electrocardiogram
analyzed by per protocol
analysis was 91.6% and
67.3% respectively in test
group, which was 69.2%
and 61.2% respectively in
control group
Adverse events 5
patients(1.5%) in test
group while no adverse
in control group
Safﬂor yellow
injection at a dose
of 5 ml is effective
and safe for the
treatment of
angina pectoris
with heart-blood
stagnation
syndrome in
patients with CHD
Liu et al.
(2011a)
3 weeks CHD 127, 62 in group
treated with safﬂor
yellow. 65 in group
treated with usual
western medicine
(68.58 ± 10.12)
Intravenous with
80 mg safﬂor yellow
100 mg/day
Usual western
medicine treatment
Safﬂor yellow treatment
resulted in decrease of
plasma of endothelin,
matrix
metalloproteinase-9 and
high sensitivity C reactive
protein (hs-CRP) as usual
treatment
None reported Safﬂor yellow is
beneﬁcial to CHD
Liao (2012) 30 days Chronic pulmonary
heart disease
(CPHD)
68, 34 per group
(58.78 ± 1.74)
Usual treatment with
injection of 30 ml
safﬂower injection in
0.5% glucose injection
250 ml once a day
Usual treatment The parameters of blood
gas in the observation
group were signiﬁcantly
better than the control
group (p < 0.05)
None reported Safﬂower injection
has clinical value in
CPHD
Chen et al.
(2014)
10 days CPHD 72, 36 per group
(58 ± 7)
Usual treatment with
100 mg  safﬂor yellow
in 0.9% NaCl 250 ml,
30–40 drop/min
Usual treatment (7 ml
10%KCl, 4 IU insulin,
ATP, CoA and so on in
0.9% NaCl 250 ml
The improvement of ST
segment depression in
treatment group was  much
more obvious than that in
control group. The level of
troponin, phosphocreatine
kinase and hs-CRP
decreased much more than
that in control group
None reported Safﬂor yellow
displayed a good
protective effect on
CPHD
562
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Chart 2 (Continued )
Author (Date) Design duration Condition No. of participants
randomized (age)
Intervention Comparison Main results between
groups
Adverse events Authors conclusion
Ren and Mei
(2014)
14 days Chronic obstructive
pulmonary disease
(COPD)
69, 35 in treated group,
34 in control group
(63.8 ± 5.3)
Usual treatment and
injecting 150 mg safﬂor
yellow powder in 0.9%
NaCl 250 ml once a day
Usual treatment The N-terminal
pro-brain natriuretic
(NT-proBNP)was
reduced to
438.39 pg/ml from
2335.38 in treated
group while it was
reduced to
738.27 pg/ml from
2178.35 in control
group.
Hemorheology indexes
and pulmonary
ventilation function
were improved
None reported Safﬂor yellow pigment
injection combined
with western medicine
can beneﬁcial to COPD
Luo et al.
(2014)
14 days Acute cerebral
infarction (ACI)
51, 25 in treated group,
27 in control group
(35–40)
Intravenous with
safﬂower injection
(20 ml/day) and 20%
mannitol, citicoline,
taken aspirin orally
Injected with 20%
mannitol, citicoline
and taken aspirin orally
On 14th day,
neurological severity
scores (NSS) of
treatment group was
lower than that of
control group
(p = 0.040). Also, it was
resulted in serum IL-6
level decreased and
IL-10 level increased.
Positive correlation
was observed between
IL-6/IL-10 value and
NSS in treatment group
(r  = 0.997, p = 0.048),
but mot in control
group (r = 0.962,
p = 0.177)
None reported Early application of
safﬂower injection is
beneﬁcial for young
patients with ACI. The
mechanism might be
related with lowing
IL-6/IL-10 value
through decreasing
IL-6 level and
enhancing IL-10 level
Xing  et al.
(2008)
15 days Ischemic apoplexy 60, 30 per group
(65 ± 3.1)
IV drip of safﬂor yellow
100 mg  in 0.9% NaCl
250 ml
20 ml Ginkgo leaf
extract and
dipyridamole injection
in  0.9% NaCl 250 ml
The effective rate in
safﬂor yellow group
was 93.3% while 63.3%
in control group.
Safﬂor yellow showed
a  remarkable effect for
qi vacuity bloodstasis
None reported Safﬂor yellow has
favorable results in
treatment of ischemic
apoplexy
Li et al. (2011) 5 days Acute gouty
arthritis
120, 80 in safﬂower
injection group, 40 in
colchicine group
(30–58)
IV drip of safﬂower
injection in 0.9% NaCl
250 ml once a day
Taken 1 mg  colchicine
orally three times a day
Blood uric acid in both
groups decreased than
pretherapy
None reported in
safﬂower injection
group but serious
gastrointestinal
reaction happened in
29 patients of control
group
Safﬂower injection has
curative effect in acute
gouty arthritis
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Wei  (2011) 28 days Diabetic
nephropathy (DN)
93, 47 in treated group,
46 in control group
(57.2 ± 9.8)
IV drip of safﬂower
injection 20 ml once a
day and usual
treatment
Usual treatment The index of fasting
serum glucose, blood
urea nitrogen, serum
creatinine and urine
protein decreased
much more than
control group
None reported Safﬂower injection
could effectively
postponement the
development of renal
failure caused by
diabetic nephropathy
Pang et al.
(2014)
7 days Renal
transplantation
382, 231 in group
treated with safﬂor
yellow. 151 in group
with conventional
treatment (38.0 ± 13.1)
Intravenous injection
of safﬂor yellow twice
a day (10 ml per time)
and conventional
treatment
Conventional
treatment
The incidence of
delayed graft function
was lower in
observation group
(5.63%)than that in
control group (11.26%),
which is same as the
level of serum
creatinine, the renal
segmental and lobular
artery resistance
indexes
None reported Safﬂor yellow could
descend the incidence
of delayed graft
function and
ameliorate the
recovery of graft
function after renal
transplantation
Xiong and
Dong (2014)
14 days Diabetic
retinopathy (DR)
168, 92 in treatment
group, 76 in control
group (60.45 ± 6.10)
Conventional
treatment with
additional 100 ml
safﬂor yellow injection
once a day
Conventional
treatment
The total effective rates
of treatment group and
control group were
91.3% and 76.32%
respectively. The
increased serum
endostatin and
decreased vascular
endothelial growth
factor were much more
in  treated group
None reported Safﬂor yellow injection
can be used to DR in
type 2 diabetes
patients and thereby
delay the progression
of DR
Yang et al.
(2011)
14 days DN 72, 38 in treatment
group, 34 in control
group (59.0 ± 7.7)
IV drip of safﬂor yellow
100 mg in 0.9% NaCl
250 ml once a day
IV drip of 20 ml
composite salvia in
0.9% NaCl 250 ml once
a day
24 h Urine protein
serum creatinine were
decreased both in
prophase and clinical
phase than control
group
None reported Safﬂor yellow injection
was beneﬁcial to DN
treatment
Yang and Dai
(2010)
One month Diabetic peripheral
neuropathy (DPN)
84, 42 per group
(48.94 ± 7.15)
Conventional
treatment with
injecting 100 mg safﬂor
yellow to zusanli
acupoint and
sanyinjiao acupoint
Conventional
treatment with
additional 100 mg
safﬂor yellow injection
once a day
The total effective rates
of treatment group and
control group were
84.47% and 62.46%
respectively. The
treated group of
sensory threshold,
motor nerve
conduction velocity
and sensory
conduction velocity
outweigh that in
control group
None reported Acupoint injection of
safﬂor yellow could
improve nerve
conduction velocity
and decreased sensory
threshold, which may
be concerned with
ameliorating
microcirculation of
DPN patients and nerve
ischemia
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osage of 180 mg/kg for ninety days resulted in slight nephro-
oxicity in SD rats (Liu et al., 2004), whereas -terpineol induced
atty liver (Choi et al., 2013). A clinical observation also reported
arthami ﬂos as a new cause of occupational asthma, as shown by
ronchial challenges or brochial provocation tests (Compes et al.,
006). As mentioned previously, further evaluations of the systemic
oxicity and safety of Carthami ﬂos are needed.
onclusion
The available pharmacological studies on crude extracts or
dentiﬁed compounds of Carthami ﬂos provide pragmatic sup-
ort for some traditional therapeutic claims. However, there are
 number of issues that need to be addressed. First, the extensive
harmacological investigations on quinochalcone glycosides have
redominantly focused on HSYA. Its advantages in brain tissue,
yocardial tissue, diabetes mellitus, and hypertension have been
eported, and different preparations have been applied in clinical
ractice in China. However, the underlying molecular mechanisms
f action of HSYA have not been sufﬁciently clariﬁed. Consequently,
ore rigorous experiments on in vitro and in vivo systems, as well
s in human models, are required. Moreover, how to exploit other
uinochalcone glycosides remains a subject of continuing study.
econd, more systemic evaluations of Carthami ﬂos in clinical appli-
ations, including treatment of coronary heart disease, chronic
ulmonary heart disease, cerebrovascular diseases, orthopedic dis-
ases, and diabetes mellitus, need to be carried out. Third, in spite
f the distinguished activities of Carthami ﬂos in some diseases,
he side effects of its use should not be ignored, such as sper-
atogenetic failure, allergic reaction, and nephrotoxicity. Thereby,
ystemic toxicity and safety evaluations regarding Carthami ﬂos are
ecessary. In summary, the challenge for the future of Carthami
os lies in conﬁrming the mechanism underlying its effects and in
roviding brawinest clinical support.
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